Last reviewed · How we verify
Ironwood Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
4 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| XOI | XOI | marketed | Guanylate cyclase-C agonist | GC-C (guanylate cyclase-C) | Gastroenterology | |
| Microgestin® | Microgestin® | marketed | Oral contraceptive (combined estrogen-progestin) | Estrogen receptor, progesterone receptor | Contraception / Women's Health |
Therapeutic area mix
- Contraception / Women's Health · 1
- Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bayer · 1 shared drug class
- EA Pharma Co., Ltd. · 1 shared drug class
- Helsinki University Central Hospital · 1 shared drug class
- Md Mehedi Shahriar · 1 shared drug class
- Oregon Health and Science University · 1 shared drug class
- Organon and Co · 1 shared drug class
- Teva Pharmaceuticals USA · 1 shared drug class
- University of Colorado, Denver · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Ironwood Pharmaceuticals, Inc.:
- Ironwood Pharmaceuticals, Inc. pipeline updates — RSS
- Ironwood Pharmaceuticals, Inc. pipeline updates — Atom
- Ironwood Pharmaceuticals, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Ironwood Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ironwood-pharmaceuticals-inc. Accessed 2026-05-16.